The United States leads the world in developing new approaches and new technologies to prevent, diagnose, manage, and cure illness.  These innovations are a key source of health improvements.  This dashboard tracks a set of corresponding short, intermediate, and long-term indicators.  The national summary data for the measures that comprise this dashboard are presented below.

Number of Investigational New Drug Applications Granted "Fast Track" Status

Investigational new drugs are those that both sponsors and the FDA believe meet a pressing unmet medical need for a serious disease. If a drug and a particular indication receive Fast Track status, early and frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and review process. The frequency of communication assures that issues are resolved quickly, often leading to earlier drug approval and access by patients.

See this measure in detail »

Dollars Invested in Pharmaceutical and Medicine Manufacturing Research and Development

Investment in research and development work (R&D) in the field of pharmaceutical and medical manufacturing is critical to developing new and innovative medical products that improve our nation’s health and address unmet health needs.

See this measure in detail »

Number of Novel New Drug Applications Filed and Number of Novel New Drugs Approved by the Food and Drug Administration

The availability of new drugs often means new treatment options for patients, and advances in health care for the American public. For this reason, "innovation" is a key word throughout the pharmaceutical industry and the healthcare community. Each year the Food and Drug Administration approves a wide range of new brand name and generic drug products, including biologic drugs. Many are duplicate therapies that will compete in the marketplace with the same kind of products already approved. However, some are truly new and innovative chemical structures never used before in clinical practice. Such novel new drugs are often called new molecular entities (NMEs). Many of these products offer new hope for patients suffering from the conditions these products are intended to treat.

See this measure in detail »